If you have been reading about Preclinical research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
This was also the belief of geologist Palmer, who convinced Steven Jones that the helium-3 occurring naturally in Earth perhaps came from fusion involving hydrogen isotopes inside catalysts like nickel and palladium. This led their team in 1986 to independently make the same experimental setup as Fleischmann and Pons (a palladium cathode submerged in heavy water, absorbing deuterium via electrolysis). Fleischmann and Pons had much the same belief, but they calculated the pressure to be of 1027 atmospheres, when cold fusion experiments achieve a loading ratio of only one to one, which has only between 10,000 and 20,000 atmospheres. John R. Huizenga says they had misinterpreted the Nernst equation, leading them to believe that there was enough pressure to bring deuterons so close to each other that there would be spontaneous fusions.
The rise of field guides for the identification of birds was another major innovation. The early guides such as Thomas Bewick's two-volume guide and William Yarrell's three-volume guide were cumbersome, and mainly focused on identifying specimens in the hand. The earliest of the new generation of field guides was prepared by Florence Merriam, sister of Clinton Hart Merriam, the mammalogist. This was published in 1887 in a series Hints to Audubon Workers: Fifty Birds and How to Know Them in Grinnell's Audubon Magazine. These were followed by new field guides, from the pioneering illustrated handbooks of Frank Chapman to the classic Field Guide to the Birds by Roger Tory Peterson in 1934, to Birds of the West Indies published in 1936 by Dr. James Bond - the same who inspired the amateur ornithologist Ian Fleming in naming his famous literary spy. The interest in birdwatching grew in popularity in many parts of the world, and the possibility for amateurs to contribute to biological studies was soon realized. As early as 1916, Julian Huxley wrote a two-part article in The Auk, noting the tensions between amateurs and professionals, and suggested the possibility that the "vast army of bird lovers and bird watchers could begin providing the data scientists needed to address the fundamental problems of biology." The amateur ornithologist Harold F. Mayfield noted that the field was also funded by non-professionals. He noted that in 1975, 12% of the papers in American ornithology journals were written by persons who were not employed in biology related work.
In September 2022, Newsom signed Senate Bill 107 into law, making California the first sanctuary state for transgender youth. He issued an official state proclamation for Pride Month in June 2023, issued a fine of $1.5 million to a school district whose board rejected a curriculum including a biography of gay rights leader Harvey Milk, and signed a bill prohibiting schools from banning textbooks based on their inclusion of references to people from minority groups or the LGBT community. In July 2024, he signed the "SAFETY Act", which prohibits schools from outing students' gender identity to their parents without the students' consent. Newsom later vetoed several bills that the Assembly had passed by a wide margin, one of which would have instructed judges who preside over custody battles to take into account parents' affirmation of their children's gender identity, and one of which would have mandated that insurance plans serving California residents cover the cost of gender-affirming care. This, and later comments by Newsom on his podcast calling trans women's participation in women's sports "deeply unfair", appeared to signify a change in course in which he forsook his support of key transgender issues to appeal to right-wing audiences. He received backlash from some progressive commentators and the disapproval and condemnation of several of his fellow Democrats, such as California State Assemblyman Chris Ward and California State Senator Caroline Menjivar of the LGBTQ+ Caucus, who said his comments "profoundly sickened and frustrated" them.
Sources: en.wikipedia.org
Public sector whistleblowing is connected to the concept of public service motivation, where a public servant's altruistic alignment to the people or communities they serve overrides their adherence to their employer's rules. This connection has been demonstrated by research in many different countries, including Poland, Thailand and the United States of America. Recognition of the value of public sector whistleblowing has been growing over the last 50 years. Many jurisdictions have passed legislation to protect public service whistleblowing in part as a way to address unethical behaviour and corruption within public service agencies. In the United States, for example, both state and Federal statutes have been put in place to protect whistleblowers from retaliation. The United States Supreme Court ruled that public sector whistleblowers are protected from retaliation by their First Amendment rights. After many federal whistleblowers were covered in high-profile media cases, laws were finally introduced to protect government whistleblowers. These laws were enacted to help prevent corruption and encourage people to expose misconduct, illegal, or dishonest activity for the good of society. People who choose to act as whistleblowers often suffer retaliation from their employer. They most likely are fired because they are an at-will employee, which means they can be fired without a reason. There are exceptions in place for whistleblowers who are at-will employees. Even without a statute, numerous decisions encourage and protect whistleblowing on grounds of public policy.
A 2016 paper describes the efforts of how ansuvimab was originally developed as part of research efforts led by Dr. Nancy Sullivan at the United States National Institutes of Health Vaccine Research Center and Dr. J. J. Muyembe-Tamfum from the Institut National de Recherche Biomedicale (INRB) in the Democratic Republic of Congo. This collaborative effort also involved researchers from Institute of Biomedical Research and the United States Army Medical Research Institute of Infectious Diseases. A survivor from the 1995 outbreak of Ebola virus disease in Kikwit, Democratic Republic of Congo donated blood to the project that began roughly ten years after they had recovered. Memory B cells isolated from the survivor's blood were immortalized, cultured and screened for their ability to produce monoclonal antibodies that reacted with the glycoprotein of Ebola virus. Ansuvimab was identified from one of these cultures and the antibody heavy and light chain gene sequences were sequenced from the cells. These sequences were then cloned into recombinant DNA plasmids and purified antibody protein for initial studies was produced in cells derived from HEK 293 cells.
==== Dick's screenplay ==== Dick's screenplay features numerous scenes that are not in the novel. According to Tim Powers, a friend of Dick's and fellow science fiction writer, in his foreword to Ubik: The Screenplay, Dick had an idea for the film that involved "the film itself appearing to undergo a series of reversions: to black-and-white, then to the awkward jerkiness of very early movies, then to a crookedly jammed frame which proceeds to blacken, bubble and melt away, leaving only the white glare of the projection bulb, which in turn deteriorates to leave the theater in darkness, and might almost leave the moviegoer wondering what sort of dilapidated, antique jalopy he'll find his car-keys fitting when he goes outside".
==== Agent Abrella ==== Rainian Agent Abrella (レイン星人エージェント・アブレラ, Rein Seijin Ējento Aburera) is a bat-themed arms dealer from Planet Rain and an infamous figure in the intergalactic black market who is known for causing wars in seven galaxies, destroying billions of lives in the process. As his homeworld's name suggests, it is perpetually raining, forcing him to wear a special helmet that produces an artificial rainy environment to sustain himself on other worlds. After arriving on Earth, he offers his services, as well as Mechanoids and Kaijuki, to his fellow Alienizers for the right price. Initially staying in the shadows, Abrella gathers information on the Deka Base from clients who have successfully infiltrated it and escaped with their lives while planning to eventually realize his desire for a "world of...currency and crime". After eventually making his presence known to the Dekarangers and losing a Browgoul he intended to raise to them, Abrella starts taking their interference personally and launches a failed smear campaign against them. Following this, Abrella takes advantage of the Dekarangers' fight with the Alienizer Jellyfis to break four Alienizers out of prison and lead them in taking over the Deka Base. From there, he uses Deka Base Robo to go on a rampage, lure the bulk of S.P.D.'s forces to Earth, and uses their planetary forcefield against them. While the Dekarangers eventually retake Deka Base Robo and use the D-Bazooka to delete Abrella, he was succeeded by his pupil, Agent X, as of the crossover film Mahō Sentai Magiranger vs. Dekaranger.
Sources: en.wikipedia.org
A 2018 American Academy of Periodontology best-evidence consensus statement concluded that, as an adjunct to conventional periodontal therapy, appropriately applied laser therapy may provide a modest additional benefit (<1 mm) in probing depth reduction and clinical attachment level compared with conventional therapy, but that evidence is inadequate to conclude that laser therapy alone is superior or comparable to conventional periodontal therapy. The same statement found evidence inadequate to conclude an additional benefit for residual pockets after conventional therapy and at least one year of periodontal maintenance care. European Federation of Periodontology guidance for treatment of stage I–III periodontitis states that lasers as an adjunct to subgingival instrumentation are not suggested.
== Mechanical properties == Implementing MOFs in industry necessitates a thorough understanding of the mechanical properties since most processing techniques (e.g., extrusion and pelletization) expose the MOFs to substantial mechanical compressive stresses. The mechanical response of porous structures is of interest as these structures can exhibit unusual response to high pressures. While zeolites (microporous, aluminosilicate minerals) can give some insights into the mechanical response of MOFs, the presence of organic linkers as opposed to zeolites, makes for novel mechanical responses. MOFs are structurally diverse meaning that it is challenging to classify all of their mechanical properties. Additionally, variability in MOFs from batch to batch and extreme experimental conditions (diamond anvil cells) mean that experimental determination of mechanical response to loading is limited, however many computational models have been made to determine structure-property relationships. Main MOF systems that have been explored are zeolitic imidazolate frameworks (ZIFs), Carboxylate MOFs, Zirconium-based MOFs, among others. Generally, the MOFs undergo three processes under compressive loading (which is relevant in a processing context): amorphization, hyperfilling, and/or pressure induced phase transitions. During amorphization linkers buckle and the internal porosity within the MOF collapses. During hyperfilling the MOF which is being hydrostatically compressed in a liquid (typically solvent) will expand rather than contract due to a filling of pores with the loading media.
After the Dissolution of the Soviet Union in 1990, Cuba lost access to its primary financial partners, and was facing a massive economic collapse. In order to stave off the effects of economic isolation, they authorized the transformation of formerly state-owned enterprise into a new kind of joint private-public company to develop hotels and rejuvenate Cuba's tourism sector. The Communist Party of Cuba allowed Cuban civil society organizations to reform, allowing hundreds of non-governmental organizations to form in Havana, and especially relaxed its regulations on membership in Catholic Church. They relaxed regulations on international charities, including Caritas Internationalis. When the World Wide Web was created in 1991, Cuba authorized its citizens access to the internet. In 1991, the Congress of the Communist Party of Cuba officially authorized registered Communists to join the Freemasons (and churches). Membership in the Grand Lodge of Cuba rose sharply, and Cuba fully opened the country to Freemasonry. Masons were allowed to attend public events adorned in Masonic regalia. New lodges were opened across the country. Freemasons were also allowed to lay wreaths at the graves of deceased Brothers. After 1991, newly initiated Freemasons included high-ranking leaders of the Communist Party, government officials, members of Cuban dissident movements, antigovernment activists, and others. In 1993, Caridad del Rosario Diego Bello was appointed head of OAR.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.